The American Pharmaceutical Company Merck stated that the regulator of the European Union in the field of medicines (EMA) began checking the tablets from Coronavirus, reports Al Arabiyya.
According to the verification procedure, the Agency will evaluate the data in real time, that is, as soon as they become available.
Although vaccines are the main “weapons” against COVID-19, Merck tablets can change the situation after the studies will show the results.
The company itself reports that the tablets from Coronavirus twice the risk of death and hospitalization, especially at risk of a group of people.
Note that October 11, MERCK filed an application for permission to use the drug in the US Emergency Situations.
medicine, if it is approved by regulatory authorities, will be the first preparation from COVID-19 with oral administration, as well as the first tool for the treatment of patients with light diseases, while existing drugs are mainly used to treat critical patients.
The manufacturer already has a contract with the US government for the supply of 1.7 million courses of the drug at a price of 700 dollars per course. Also Merck recently signed a supply agreement with the United Kingdom, Malaysia and Singapore.